Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03976245

Advanced Therapeutics in Rheumatoid Arthritis (RA)

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
144 (estimated)
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).

Detailed description

Conventional therapies for Rheumatoid Arthritis (RA) treatment include nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) selective inhibitors, corticosteroids and disease modifying anti-rheumatic drugs (DMARDs). These therapies are often partially effective. For those patients, where conventional therapies have failed to alleviate their symptoms, Tumour Necrosis Factor (TNFis) is often prescribed to treat the pain and inflammation associated with RA. The main problem with TNFi and other advanced therapies in RA is retention. At least ¼ of patients stop treatment within a year and another ⅕ to ¼ in the second year, mostly due to secondary loss of efficacy. Another advanced therapy, the Janus kinase inhibitor (JAK) has demonstrated similar efficacy to TNFi treatment in RA. This trial will determine if using a different class of treatment (small molecule, oral drug, JAK kinase inhibitor) will have a better retention than a TNFi (using the most commonly prescribed TNFi for RA in Canada).

Conditions

Interventions

TypeNameDescription
DRUGEtanerceptinjection
DRUGtofacitinibtablet

Timeline

Start date
2020-03-01
Primary completion
2025-03-01
Completion
2025-03-01
First posted
2019-06-05
Last updated
2024-11-29

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03976245. Inclusion in this directory is not an endorsement.